secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001628280-24-041541
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine inks $110M upfront BMS collaboration, refocuses pipeline, cash runway to H1 2026
--------------------------------------------------------------------------------

- Received $55M upfront + $55M equity investment ($5.00/share) from BMS for exclusive license to Prime Editing for ex vivo T-cell therapies.
- Up to >$3.5B in milestones ($1.4B development, >$2.1B commercialization) plus tiered royalties; BMS locked up shares until Sep 2027.
- Pipeline focus: Phase 1/2 CGD data expected in 2025; Wilson's Disease IND/CTA planned for H1 2026.
- X-linked CGD program added using PASSIGE technology; cystic fibrosis work continues with CFF funding.
- Cost savings plus BMS upfront extend cash runway into first half of 2026 (previously not guided beyond 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024041541/0001628280-24-041541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024041541/prme-20240928.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-041541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer